These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27084254)

  • 21. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura.
    Szende A; Brazier J; Schaefer C; Deuson R; Isitt JJ; Vyas P
    Curr Med Res Opin; 2010 Aug; 26(8):1893-903. PubMed ID: 20553121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study.
    Nørgaard M; Cetin K; Maegbaek ML; Kristensen NR; Ghanima W; Bahmanyar S; Stryker S; Christiansen CF
    Br J Haematol; 2016 Aug; 174(4):639-42. PubMed ID: 26456477
    [No Abstract]   [Full Text] [Related]  

  • 23. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports.
    Terrell DR; Beebe LA; Vesely SK; Neas BR; Segal JB; George JN
    Am J Hematol; 2010 Mar; 85(3):174-80. PubMed ID: 20131303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epidemiology and pharmacoepidemiology of immune thrombocytopenia].
    Moulis G; Lapeyre-Mestre M; Adoue D; Sailler L
    Rev Med Interne; 2017 Jul; 38(7):444-449. PubMed ID: 28131440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings.
    Rizvi H; Butler T; Calaminici M; Doobaree IU; Nandigam RC; Bennett D; Provan D; Newland AC
    Br J Haematol; 2015 May; 169(4):590-4. PubMed ID: 25753327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
    Liebman HA; Pullarkat V
    Hematology Am Soc Hematol Educ Program; 2011; 2011():384-90. PubMed ID: 22160062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of cataract among idiopathic thrombocytopenic purpura patients in the UK general practice research database.
    Feudjo-Tepie MA; Hall SA; Logie J; Robinson NJ
    Pharmacoepidemiol Drug Saf; 2009 May; 18(5):380-5. PubMed ID: 19241439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FCGR2A rs1801274 polymorphism is associated with risk of childhood-onset idiopathic (immune) thrombocytopenic purpura: evidence from a meta-analysis.
    Wang D; Hu SL; Cheng XL; Yang JY
    Thromb Res; 2014 Dec; 134(6):1323-7. PubMed ID: 25457587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy.
    Buchbinder D; Nugent D; Hsieh L
    Drug Des Devel Ther; 2017; 11():1055-1063. PubMed ID: 28408804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of diagnosed adult immune thrombocytopenia in the United Kingdom.
    Bennett D; Hodgson ME; Shukla A; Logie JW
    Adv Ther; 2011 Dec; 28(12):1096-104. PubMed ID: 22139790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M; Rubinstein PG; Aboulafia DM
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors and current management of venous thromboembolism in patients with primary immune thrombocytopenic purpura.
    Tana M; Tana C; Rizzo G; Ricci F; Porreca E
    Eur J Intern Med; 2021 Apr; 86():121-123. PubMed ID: 33568328
    [No Abstract]   [Full Text] [Related]  

  • 34. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database.
    Schoonen WM; Kucera G; Coalson J; Li L; Rutstein M; Mowat F; Fryzek J; Kaye JA
    Br J Haematol; 2009 Apr; 145(2):235-44. PubMed ID: 19245432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low neonatal risk of thrombocytopenia in pregnancy associated with immune thrombocytopenic purpura.
    Song TB; Lee JY; Kim YH; Choi YY
    Fetal Diagn Ther; 1999; 14(4):216-9. PubMed ID: 10420044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).
    Sanz MA; Aledort L; Mathias SD; Wang X; Isitt JJ
    Value Health; 2011 Jan; 14(1):90-6. PubMed ID: 21211490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
    Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
    Lam MS
    J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study.
    Frederiksen H; Maegbaek ML; Nørgaard M
    Br J Haematol; 2014 Jul; 166(2):260-7. PubMed ID: 24690142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.